PRMT5 inhibitor as well as preparation method and pharmaceutical application thereof

CN119013275APending Publication Date: 2024-11-22ABBISKO THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033451.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-10
Filing Date
2023-07-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current technologies struggle to target PRMT5 in MTAP-deficient tumor cells while avoiding side effects in normal cells, resulting in an insufficient therapeutic window for PRMT5 inhibitors.

Method used

A PRMT5 inhibitor has been developed, the preparation of which involves a compound with a specific structure that can selectively target PRMT5 in the MTA-bound state, reducing the impact on normal cells.

Benefits of technology

It provides a therapeutic window for effectively inhibiting PRMT5 in MTAP-deficient tumor cells, reduces side effects on normal cells, and has broad potential for treating and preventing PRMT5-mediated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013275A_ABST
    Figure CN119013275A_ABST
Patent Text Reader

Abstract

The invention relates to a PRMT5 inhibitor, a preparation method thereof and a pharmaceutical application of the PRMT5 inhibitor. The invention relates to the field of medicines, in particular to a PRMT5 inhibitor with a structure as shown in a formula (I), a preparation method of the PRMT5 inhibitor, a pharmaceutical composition containing the PRMT5 inhibitor, application of the PRMT5 inhibitor as the PRMT5 inhibitor and application of the PRMT5 inhibitor in treatment and / or prevention of PRMT5-mediated diseases. Wherein each substituent in the formula (I) is as defined in the specification. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

A PRMT5 inhibitor, its preparation method and pharmaceutical application Technical Field

[0001] The present invention belongs to the field of drug synthesis, and specifically relates to a PRMT5 inhibitor, a preparation method thereof and pharmaceutical applications. Background Art

[0002] Epigenetic gene regulation is an important biological regulatory mechanism for protein synthesis and cell differentiation, and plays an important role in many human diseases.

[0003] Epigenetic regulation involves the manipulation of inherited genetic material without altering its nucleic acid sequence. Typically, epigenetic regulation is achieved by selective and reversible modifications (e.g., methylation) of DNA and proteins (e.g., histones) to control the transition between transcriptionally active and inactive states of chromatin conformation. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., PRMT5), many of which are associated with specific genetic alterations in numerous human disease-causing genes. PRMT5 plays a crucial role in numerous diseases, including cancer, metabolic disorders, and hematologic diseases.

[0004] Homozygous deletion of tumor suppressor genes is a tumor driver and often results in the loss of nearby passenger genes. Loss of these passenger genes confers tumor cell-specific vulnerabilities that can be targeted with targeted therapies. Homozygous deletion of chromosome 9p21, encompassing the well-known tumor suppressor gene CDKN2A, occurs in 15% of tumors and often includes loss of the passenger gene MTAP. MTAP is a key enzyme in the methionine and adenine recycling pathway. Loss of MTAP leads to the accumulation of its substrate, MTA. MTA shares structural similarities with S-adenosylmethionine (SAM), the methyl group donor for the type II methyltransferase PRMT5. Elevated MTA levels due to MTAP loss selectively compete with SAM for PRMT5 binding, rendering the methyltransferase inactive and susceptible to PRMT5 inhibition. A variety of genome-wide shRNA screens across a wide range of tumor cell lines have demonstrated a correlation between MTAP deficiency and cell line dependence on PRMT5, placing the impact of this metabolic vulnerability in the spotlight. However, as PRMT5 is a critical gene for cells, studies using conditional knockout or siRNA knockdown of PRMT5 have suggested that inhibiting PRMT5 in normal tissues can have significant side effects (e.g., cytopenias, infertility, skeletal muscle loss, cardiac hypertrophy, etc.). Therefore, new strategies are needed to exploit and explore this metabolic vulnerability, selectively targeting PRMT5 in MTAP-deficient tumors while avoiding its effects in normal tissues (MTAP wild-type).

[0005] Small molecule inhibitors targeting PRMT5 that collaborate with MTA can selectively target only PRMT5 in the MTA-bound state, and this PRMT5 is only enriched in tumor cells that lack MTAP. Therefore, in normal cells with intact MTAP, when MTA levels are very low, PRMT5 will not be targeted, thus providing a better therapeutic window.

[0006] Summary of the Invention

[0007] The present invention aims to provide a PRMT5 inhibitor, its preparation method, and pharmaceutical application. The compounds of the present invention have a strong inhibitory effect on PRMT5 and can be widely used to prepare drugs for treating and / or preventing PRMT5-mediated diseases, thus promising the development of a new generation of PRMT5 inhibitors.

[0008] The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0009] wherein X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N;

[0010] Ring A is C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, and the C 3-10 The cycloalkyl group or the 4-10 membered heterocyclic group is further fused to C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is further fused to C 3-10 Cycloalkyl or 4-10 membered heterocyclic group;

[0011] Ring B is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0012] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0013] R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0014] R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 12 R 13 substituted by a substituent;

[0015] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O)r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0016] R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11)2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 ;

[0017] Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0018] Each R 10 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0019] Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0020] Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or

[0021] R 12 and R 13Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent;

[0022] Each r is independently 0, 1, or 2;

[0023] m is selected from 0, 1, 2, 3, 4, 5 or 6; and

[0024] n is selected from 0, 1, 2, 3, 4 or 5.

[0025] As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring A is C 3-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl, and the C 3-8 The cycloalkyl or 4-8 membered heterocyclic group is further fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is further fused to C 3-8 Cycloalkyl or 4-8 membered heterocyclic group;

[0026] Ring B is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl;

[0027] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11)2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0028] R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0029] R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 12 R 13 substituted by a substituent;

[0030] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;

[0031] R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 ;

[0032] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as defined for the compound of formula (I).

[0033] As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0034] Each R 10 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0035] Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;

[0036] Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or

[0037] R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.

[0038] As a preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following structure of the compound of formula (II):

[0039] wherein X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N;

[0040] Y1 is CR 1a or N; Y2 is CR 1b or N; Y3 is CR 1c or N; Y4 is CR 1d or N;

[0041] Z is -C(R 1e R 1f )-、-C(R 1e R 1f )O-、-N(R 1g )-, -O-, or -S-;

[0042] Ring B is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl;

[0043] R 1a 、R 1b 、R 1c 、R 1d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0044] R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 , or, R 1e and R 1f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0045] R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0046] Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R11 substituted by a substituent;

[0047] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR 10 and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0048] R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR12 R 13 substituted by a substituent;

[0049] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0050] R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ;

[0051] o is 0, 1, 2, or 3;

[0052] m1 is 0, 1, or 2;

[0053] Among them, R9, R 10 、R 11 、R 12 、R 13 , n and r are as defined for the compound of formula (I).

[0054] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring B and the part directly connected thereto together form the following structure:

[0055] Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0056] Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0057] Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0058] X1 is CR6 or N, each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;

[0059] X2 is CR7 or N, each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;

[0060] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;

[0061] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as defined for the compound of formula (II).

[0062] As a preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following compound structure of formula (III):

[0063] Wherein, X1 is CR6 or N; X2 is CR7 or N;

[0064] Y1 is CR 1a or N; Y2 is CR 1b or N;

[0065] Z is -C(R 1e R 1f )-、-C(R 1e R 1f )O-、-N(R 1g )-or-O-;

[0066] Ring B together with its directly connected parts forms the following structure:

[0067] R 1a 、R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0068] R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0069] R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, hydroxyl, C 1-4 Alkoxy and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0070] Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0071] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR10 and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0072] Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0073] Each R 5bare each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0074] Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、 -C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R11 substituted by a substituent;

[0075] R6 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ;

[0076] R7 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ;

[0077] R8 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ;

[0078] o is 1 or 2;

[0079] m1 is 0, 1, or 2;

[0080] Among them, R9, R 10 、R 11 、R 12 、R 13 , n and r are as defined for the compound of formula (I).

[0081] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Y1 is CH or N; Y2 is CR 1b ;

[0082] R 1b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0083] Among them, R 10 As defined for the compound of formula (III).

[0084] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0085] R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, hydroxyl, methoxy and acetyl, the above groups are independently optionally further selected from one or more of the above groups are independently optionally further selected from one or more of deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0086] Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0087] Among them, R 10 As defined for the compound of formula (III).

[0088] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,

[0089] Each X1 is independently CR6 or N; each X2 is independently CH;

[0090] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;

[0091] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;

[0092] Among them, R 10 As defined for the compound of formula (III).

[0093] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0094] Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0095] Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5;

[0096] Among them, R 10 As defined for the compound of formula (III).

[0097] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;

[0098] Among them, R9, R 10 、R 11 、R 12 、R 13 As defined for the compound of formula (III).

[0099] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, and the above groups are independently optionally further replaced by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuterated methyl , dideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, carboxyl, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropyloxycarbonyl, formyl, acetyl, n-propionyl, isopropionyl, formyloxy, acetoxy, n-propionyloxy, isopropionyloxy, amino, mono C 1-4 Alkylamino and di-C 1-4 The amino group is substituted by an alkylamino group.

[0100] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Selected from the following structures:

[0101] Each R 1b Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, trifluoromethoxy, difluoromethoxy, trideuteriomethoxy, dideuteriomethoxy, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, phenyl and methyl-substituted pyrazolyl.

[0102] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Selected from the following structures:

[0103] Each R 1b Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, trifluoromethoxy, difluoromethoxy, trideuteriomethoxy, dideuteriomethoxy, cyclopropyl and methyl-substituted pyrazolyl.

[0104] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following compound structure of formula (IVa):

[0105] in, Selected from the following structures: Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl;

[0106] Ring B and its directly connected part Selected from the following structures:

[0107] Each X1 is independently CR6 or N;

[0108] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy;

[0109] Each R 5a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5;

[0110] Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5;

[0111] R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, the above groups are independently optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, substituted by pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, hydroxyl and methoxy substituents; provided that when R2 is selected from methyl, Not for

[0112] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl;

[0113] R6 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy;

[0114] R2 is selected from cyclopropyl-substituted methyl, cyclobutyl-substituted methyl, thiazolyl-substituted methyl, pyrimidinyl-substituted methyl, ethyl, cyclopropyl-substituted ethyl, cyclobutyl-substituted ethyl, 2,2,2-trifluoroethyl, methoxyethyl, thiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, cyclopropyl, methyl-substituted pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl.

[0115] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) has the following compound structure of formula (Va):

[0116] in, Selected from the following structures: Each R 1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy and cyclopropyl;

[0117] R6 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.

[0118] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) has the following compound structure (IVb):

[0119] in, Selected from the following structures: Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl;

[0120] Ring B and its directly connected part Selected from the following structures:

[0121] Each X1 is independently CR6 or N;

[0122] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy;

[0123] Each R 5a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5;

[0124] Each R 5b Each is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl and hydroxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5;

[0125] Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5;

[0126] wherein R2 is as defined for the compound of formula (III).

[0127] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the portion of ring B directly connected to it is Selected from the following structures:

[0128] Each X1 is independently CR6; each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl;

[0129] Each R 5a are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl;

[0130] Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl;

[0131] Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.

[0132] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from substituted methyl, substituted ethyl, substituted or unsubstituted n-propyl, substituted isopropyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl,

[0133] The substituents of the substituted methyl, substituted ethyl, substituted n-propyl and substituted isopropyl are each independently one or more selected from fluorine, chlorine, bromine, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, -SF5, hydroxyl and methoxy,

[0134] The bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl are each independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, hydroxyl and methoxy.

[0135] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from substituted methyl, substituted ethyl, substituted or unsubstituted n-propyl, substituted isopropyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl,

[0136] The substituents of the substituted methyl, substituted ethyl, substituted n-propyl and substituted isopropyl are each independently one or more selected from fluorine, chlorine, bromine, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl and methoxy,

[0137] The phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl groups are each independently further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, cyclopropyl, -SF5, hydroxyl and methoxy.

[0138] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from trifluoromethyl, pyrazolyl-substituted methyl, imidazolyl-substituted methyl, triazolyl-substituted methyl, oxazolyl-substituted methyl, thiazolyl-substituted methyl, isothiazolyl-substituted methyl, thiadiazolyl-substituted methyl, pyrimidinyl-substituted methyl, fluoro-substituted ethyl, methoxyethyl, pyrazolyl-substituted ethyl, imidazolyl-substituted ethyl, triazolyl-substituted ethyl, oxazolyl substituted ethyl, thiazolyl-substituted ethyl, isothiazolyl-substituted ethyl, thiadiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, pyrazolyl, methyl-substituted pyrazolyl, imidazolyl, methyl-substituted imidazolyl, triazolyl, methyl-substituted triazolyl, oxazolyl, methyl-substituted oxazolyl, thiazolyl, methyl-substituted thiazolyl, isothiazolyl, methyl-substituted isothiazolyl, thiadiazolyl, methyl-substituted thiadiazolyl, pyrimidinyl and methyl-substituted pyrimidinyl.

[0139] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from thiazolyl-substituted methyl, pyrimidinyl-substituted methyl, 2,2,2-trifluoroethyl, methoxyethyl, thiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, methyl-substituted pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl.

[0140] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R2 is selected from the following structures:

[0141] As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) have the following structures: compounds of formula (Vb1), (Vb2), (Vb3), and (Vb4):

[0142] Each R 1b each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy and cyclopropyl;

[0143] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano and methyl;

[0144] Each R 5b Each is independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuterium and cyclopropyl.

[0145] As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:

[0146] The second aspect of the present invention provides a method for preparing a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, the preparation method comprising the following steps:

[0147] wherein X is fluorine, chlorine, bromine or hydroxyl, and ring A, ring B, X1, X2, X3, R1, R2, R3, R4, R5, m and n are as described for the compound of formula (I).

[0148] The third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0149] The fourth aspect of the present invention provides a use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating MATP-related cancers or tumors.

[0150] As a preferred embodiment, the tumor or cancer is selected from endometrial adenocarcinoma, granulosa-theca cell tumor, testicular Sertoli cell tumor, germ cell tumor, malignant teratoma, squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma, clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, fallopian tube cancer, adenocarcinoma, Wilms' tumor, lymphoma, leukemia, bladder cancer, squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, prostate cancer, seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor , lipoma; liver cancer, bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary cancer, bile duct cancer, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi sarcoma, nevus, dysplastic nevus, lipoma, hemangioma, acute and chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin's lymphoma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma , multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma, benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, giant cell tumor, angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma, bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma, gastric cancer, lymphoma, leiomyosarcoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor , viper tumor, adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma, colorectal adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma, skull tumor, hemangioma, granuloma, xanthomas, osteitis deformans, meningioma, meningiosarcoma, gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor, spinal neurofibroma, meningioma, glioma or sarcoma.

[0151] As a more preferred embodiment, the cancer or tumor is selected from breast cancer, pancreatic cancer, skin cancer, bladder cancer, liver cancer or head and neck cancer.

[0152] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, which are used as PRMT5 inhibitor drugs.

[0153] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases.

[0154] The present invention also relates to a method for treating and / or preventing a disease mediated by PRMT5, comprising administering a therapeutically effective amount of the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a patient in need thereof. DETAILED DESCRIPTION

[0155] After extensive and in-depth research, the inventors of this application have developed for the first time a PRMT5 inhibitor having the structure of Formula (I) below. The compounds of this invention can be widely used in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases and are expected to be developed into a new generation of PRMT5 inhibitors. Based on this, the present invention was completed.

[0156] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.

[0157] "Alkyl" refers to a straight chain or branched saturated aliphatic hydrocarbon group, preferably including straight chain alkyl groups and branched alkyl groups of 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl ... Methylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or various branched chain isomers thereof. “C 1-10 "Alkyl" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups containing 1 to 4 carbon atoms, "C 0-8 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups including 0 to 8 carbon atoms, "C 0-4 The term "alkyl" refers to straight-chain and branched-chain alkyl groups having 0 to 4 carbon atoms.

[0158] Alkyl groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0159] "Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl is divided into monocyclic cycloalkyl and polycyclic cycloalkyl, preferably a cycloalkyl containing 3 to 12, 3 to 8 or 3 to 6 carbon atoms, for example, "C 3-12 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 12 carbon atoms, "C 4-8 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 8 carbon atoms, "C 3-8"Cycloalkyl" refers to a cycloalkyl group comprising 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 6 carbon atoms, wherein:

[0160] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.

[0161] Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:

[0162] "Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:

[0163] "Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:

[0164] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.

[0165] "Cycloalkyl" or "carbocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0166] "Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) r (wherein r is an integer of 0, 1, or 2), but excluding the ring portion of -OO-, -OS-, or -SS-, the remaining ring atoms are carbon. Preferably, the heterocyclyl group comprises 3 to 12, 3 to 8, or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 6 ring atoms, "3-8 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 8 ring atoms, "4-8 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 8 ring atoms, "4-10 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 10 ring atoms, "5-8 membered heterocyclyl" refers to a heterocyclyl group comprising 5 to 8 ring atoms, and "3-12 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 12 ring atoms.

[0167] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.

[0168] Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the single rings share an atom (called a spiro atom), wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O). r (where r is an integer 0, 1, or 2) with the remaining ring atoms being carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are classified as monospiro heterocyclic groups, dispiro heterocyclic groups, or polyspiro heterocyclic groups based on the number of spiro atoms shared between the rings. Spiro heterocyclic groups include, but are not limited to:

[0169] "Fused heterocyclyl" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with the other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclic groups include, but are not limited to:

[0170] "Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, these may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclic groups include, but are not limited to:

[0171] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:

[0172] "Heterocyclyl" or "heterocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0173] "Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably an all-carbon aromatic group containing 6-10 or 6-8 carbon atoms, for example, "C 6-10 "Aryl" refers to an all-carbon aromatic group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl. 6-8 "Aryl" refers to an all-carbon aromatic group containing 6-8 carbon atoms. The aromatic ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aromatic ring, including but not limited to:

[0174] "Aryl" or "aromatic ring" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0175] "Heteroaryl" or "heteroaromatic ring" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N·O and S(O)r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:

[0176] "Heteroaryl" or "heteroaromatic ring" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0177] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched alkenyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl containing 2 to 10 carbon atoms. 2-4 "Alkenyl" refers to a straight or branched chain alkenyl group containing 2 to 4 carbon atoms, including but not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.

[0178] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0179] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.

[0180] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0181] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, "C 1-10 "Alkoxy" refers to an alkyloxy group containing 1 to 10 carbon atoms. 1-4 "Alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms. 1-2 The term "alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.

[0182] "Alkoxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0183] "Cycloalkoxy" or "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above, for example, "C 3-12 "Cycloalkyloxy" refers to a cycloalkyloxy group containing 3 to 12 carbon atoms. 3-6 The term "cycloalkyloxy" refers to cycloalkyloxy groups containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

[0184] "Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0185] "Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.

[0186] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.

[0187] “C 1-10 "Alkanoyl" refers to C 1-10 The monovalent atomic group remaining after removing the hydroxyl group from the alkyl acid is usually expressed as "C 0-9 "C1 alkyl-C(O)-" refers to acetyl; "C2 alkyl-C(O)-" refers to propionyl; "C3 alkyl-C(O)-" refers to butyryl or isobutyryl.

[0188] "-C 0-8 Alkyl-OS(O)2R9" refers to the oxygen atom in -OS(O)2R9 attached to the C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0189] "-C 0-8 Alkyl-S(O) r R9" refers to -S(O) rThe sulfur atom in R9 is connected to the C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0190] "-C 0-8 Alkyl-OR 10 " refers to -OR 10 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0191] "-C 0-8 Alkyl-C(O)OR 10 " refers to -C(O)OR 10 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0192] "-C 0-8 Alkyl-C(O)SR 10 ” refers to -C(O)SR 10 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0193] "-C 0-8 Alkyl-SC(O)R 11 ” refers to -SC(O)R 11 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0194] "-C 0-8 Alkyl-C(O)R 11 ” refers to -C(O)R 11 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0195] "-C 0-8 Alkyl-OC(O)R 11 ” refers to -OC(O)R 11 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0196] "-C 0-8 Alkyl-P(O)(R 11 )2” refers to -P(O)(R 11 )2 in which the phosphorus atom is connected to the C 0-8 On the alkyl group, where C0-8 Alkyl is as defined above.

[0197] "-C 0-8 Alkyl-NR 12 R 13 ” refers to -NR 12 R 13 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0198] "-C 0-8 Alkyl-C(O)NR 12 R 13 ” refers to -C(O)NR 12 R 13 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0199] "-C 0-8 Alkyl-N(R 12 )-C(O)R 11 ” refers to -N(R 12 )-C(O)R 11 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0200] "Halogen-substituted C 1-10 The term "alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl and tribromomethyl.

[0201] "Halogen-substituted C 1-10 "Alkoxy" refers to an alkoxy group of 1-10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms. It includes but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.

[0202] "Deuterium replaces C 1-10 "Alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.

[0203] “Halogen” refers to fluorine, chlorine, bromine or iodine, “EA” refers to ethanol, “PE” refers to petroleum ether, “EtOAc” refers to ethyl acetate, “MeOH” refers to methanol, “DCM” refers to dichloromethane, and “DMSO” refers to dimethyl sulfoxide.

[0204] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.

[0205] "Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).

[0206] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.

[0207] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.

[0208] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0209] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.

[0210] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.

[0211] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150×4.6 mm column).

[0212] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0213] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.

[0214] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).

[0215] Preparation of an intermediate

[0216] Preparation of intermediate 1, 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid

[0217] Step 1: Synthesis of methyl 4-amino-5-bromo-2-fluorobenzoate

[0218] Methyl 4-amino-2-fluorobenzoate (20.8 g, 123.0 mmol) was dissolved in chloroform (500 mL). N-bromosuccinimide (21.89 g, 123.0 mmol) was added at 0°C and stirred at 20°C for 16 hours. The reaction solution was concentrated by rotary evaporation, and the crude product was separated by normal phase column chromatography to obtain methyl 4-amino-5-bromo-2-fluorobenzoate (27.9 g, 112.5 mmol, 91%). MS m / z (ESI): 247.9, 250.0 [M+H] + .

[0219] 1 H NMR (400MHz, CDCl3) δ8.04 (d, J = 7.2Hz, 1H), 6.46 (d, J = 12.2Hz, 1H), 4.62 (s, 2H), 3.88 (s, 3H).

[0220] Step 2: Synthesis of methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

[0221] Methyl 4-amino-5-bromo-2-fluorobenzoate (27.9 g, 112.5 mmol) and pinacol diboronate (35 mL, 135 mmol) were dissolved in dioxane (300 mL). Potassium acetate (33.12 g, 337.4 mmol) and 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride (8.23 g, 11.2 mmol) were added. The mixture was stirred at 100°C for 18 hours. The reaction mixture was filtered and dried by rotary evaporation. The crude product was diluted with water and extracted three times with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation. The crude product was separated by normal phase column chromatography to obtain methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (25.2 g, 85.4 mmol, 76%). MS m / z(ESI):296.2[M+H] + .

[0222] 1 H NMR (400MHz, CDCl3) δ8.25 (d, J = 9.2Hz, 1H), 6.24 (d, J = 13.2Hz, 1H), 5.29 (s, 2H), 3.86 (s, 3H), 1.34 (s, 12H).

[0223] Step 3: Synthesis of methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate

[0224] 5-Bromo-1-methyl-1H-pyrazole-4-carbonitrile (9.1 g, 48.9 mmol), methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (14.4 g, 48.9 mmol), potassium carbonate (27.04 g, 195.7 mmol), and tetrakis(triphenylphosphine)palladium (7.35 g, 6.4 mmol) were added to 1,4-dioxane (100 mL) and water (100 mL) and reacted at 100°C under nitrogen for 16 hours. The organic solvent was evaporated under reduced pressure, and the mixture was filtered. The filter cake was washed with ethanol (50 mL) and dried to give methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (13.28 g, 48.4 mmol, 99%). MS m / z(ESI):275.1[M+H] + .

[0225] Step 4: Synthesis of 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid

[0226] Methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (13.28 g, 48.4 mmol) was added to tetrahydrofuran (100 mL) and water (100 mL), followed by the addition of lithium hydroxide monohydrate (4.06 g, 96.8 mmol) and allowed to react at 50°C for 16 hours. After completion of the reaction, the organic phase was dried, diluted with water, and extracted with ethyl acetate (200 mL x 6). The aqueous phase was adjusted to pH 2 with saturated potassium bisulfate, resulting in the precipitation of a large amount of solid. The solid was filtered and the filter cake was washed with water (100 mL) and acetonitrile (100 mL). The filter cake was dried to yield 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid (6.7 g, 25.7 mmol, 53%). MS m / z (ESI): 261.1 [M+H] + .

[0227] 1 H NMR (400MHz, DMSO-d6) δ8.73(d,J=8.0Hz,1H),8.27(s,1H),7.54(s,2H),7.27(d,J=13.2Hz,1H),4.38(s,3H).

[0228] Intermediates 2 to 5 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 1:

[0229] Preparation of Intermediate 6, 6-(Trifluoromethyl)benzofuran-3(2H)-one

[0230] Step 1: Synthesis of methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate

[0231] Methyl 2-hydroxy-4-(trifluoromethyl)benzoate (15.0 g, 68.1 mmol) was dissolved in acetone (200 mL), potassium carbonate (12.24 g, 88.6 mmol) was added, and methyl bromoacetate (8.42 mL, 88.6 mmol) was then added dropwise to the reaction mixture. The temperature was then raised to 55°C and the reaction was allowed to react for 18 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, the solid was filtered out, and the filter cake was washed with ethyl acetate. The filtrate was washed with saturated brine, dried, and concentrated to yield methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate (22.0 g, 64.0 mmol, 94%). MS m / z (ESI): 293.1 [M+H] + .

[0232] Step 2: Synthesis of 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid

[0233] Methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate (74.0 g, 253.2 mmol) was dissolved in a mixture of methanol (500 mL) and water (250 mL). Lithium hydroxide monohydrate (31.91 g, 759.7 mmol) was added and allowed to react at room temperature for 18 hours. After TLC analysis, the reaction solution was acidified to pH 2 with 1N hydrochloric acid. The reaction solution was concentrated to remove methanol, the aqueous phase was filtered, and the solid was washed with water. The filter cake was dried to yield 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid (61 g, 230.9 mmol, 91%). MS m / z (ESI): 265.0 [M+H] + .

[0234] Step 3: Synthesis of 6-(trifluoromethyl)benzofuran-3(2H)-one

[0235] A mixture of 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid (61 g, 230.9 mmol), acetic anhydride (377 mL, 4.02 mol), sodium acetate (28.41 g, 346.4 mmol), and acetic acid (110 mL) was heated to 150°C and reacted for 18 hours. After completion of the reaction, the reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the intermediate (42 g) was isolated by silica gel column chromatography. This intermediate was dissolved in methanol (300 mL), 1N hydrochloric acid (300 mL) was added, and the temperature was raised to 100°C and reacted for 6 hours. LCMS analysis confirmed the reaction was complete, the reaction solution was cooled to room temperature, water was added, and the solution was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the mixture was slurried with methyl tert-butyl ether (MTBE) to give 6-(trifluoromethyl)benzofuran-3(2H)-one (17.0 g, 84.1 mmol, 36%).

[0236] 1 H NMR (400MHz, CDCl3) δ7.80 (d, J=8.0Hz, 1H), 7.43 (s, 1H), 7.35 (dd, J=8.1, 1.4Hz, 1H), 4.72 (s, 2H).

[0237] Preparation of Intermediate 7, 2-(Trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one

[0238] Step 1: Synthesis of methyl 2-bromo-6-(trifluoromethyl) nicotinate

[0239] Dissolve 2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carboxylic acid (5.0 g, 24.14 mmol) and pyridine (1.95 mL, 24.14 mmol) in chlorobenzene (50 mL). Slowly add phosphorus oxybromide (4.91 mL, 48.28 mmol) in portions at room temperature. Heat to 120°C and stir for 16 hours. After completion, concentrate the reaction mixture in vacuo. Cool the concentrate to 0°C in an ice bath, then slowly add dry methanol (20 mL) that has been previously cooled with dry ice dropwise. Stir at room temperature for 1 hour. Concentrate the reaction mixture in vacuo to obtain a brown oil. Dilute the oil with water, adjust the pH to 8 with saturated sodium bicarbonate solution, and extract with ethyl acetate three times (50 mL x 3). Wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate. The concentrate was separated by silica gel column chromatography to obtain methyl 2-bromo-6-(trifluoromethyl) nicotinate (5.7 g, 83%). MS m / z (ESI): 283.9, 285.9 [M+H] + .

[0240] 1 H NMR (400MHz, CDCl3) δ8.21 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 4.00 (s, 3H).

[0241] Step 2: Synthesis of methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl) nicotinate

[0242] To a solution of methyl 2-bromo-6-(trifluoromethyl)nicotinate (5.7 g, 20.07 mmol) and methyl acrylate (4.52 mL, 50.17 mmol) in toluene (100 mL) and N,N-dimethylformamide (15 mL) were added allylpalladium(II) chloride dimer (0.37 g, 1.00 mmol), tri(o-methylphenyl)phosphine (0.61 g, 2.01 mmol), and sodium carbonate (6.38 g, 60.20 mmol). The mixture was stirred at 120°C under a nitrogen atmosphere for 16 hours. The reaction mixture was filtered, and the filter cake was washed three times with ethyl acetate (30 mL x 3). The organic phases were combined and concentrated in vacuo. The concentrate was separated by silica gel column chromatography to afford methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl)nicotinate (5.1 g, 88%). MS m / z(ESI):290.0[M+H] + .

[0243] 1 H NMR (400MHz, CDCl3) δ8.46(d,J=15.2Hz,1H),8.40(d,J=8.0Hz,1H),7.70(d,J=8.4Hz,1H),7.26(d,J=2.8Hz,1H),4.01(s,3H),3.84(s,3H).

[0244] Step 3: Synthesis of methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate

[0245] A solution of methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl) nicotinate (5.1 g, 17.63 mmol) and triphenylphosphine rhodium chloride (1.31 g, 1.41 mmol) in ethanol (50 mL) was stirred at room temperature under a hydrogen atmosphere (15 psi) for 48 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The crude product was separated by silica gel column chromatography to afford methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate (4.9 g, 95%). MS m / z (ESI): 292.1 [M+H] + .

[0246] 1 H NMR (400MHz, CDCl3) δ8.34(d,J=8.0Hz,1H),7.58(d,J=8.0Hz,1H),3.96(s,3H),3.67(s,3H),3.57(t,J=7.2Hz,2H),2.85(t,J=7.2Hz,2H).

[0247] Step 4: Synthesis of 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one

[0248] To a solution of methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate (4.9 g, 16.82 mmol) in methanol (60 mL) was added sodium methoxide (1.36 g, 25.23 mmol) portionwise. The reaction mixture was stirred at 80°C overnight. After completion of the reaction, the reaction mixture was cooled to room temperature and concentrated to yield a brown solid. The brown solid was dispersed in 12 M concentrated hydrochloric acid (60 mL) and stirred at 80°C for 3 hours. The reaction mixture was cooled to room temperature, adjusted to pH 6 with 1 M sodium hydroxide solution, and extracted with dichloromethane (100 mL x 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to yield a brown solid. The brown solid was separated by silica gel column chromatography to give 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one (2.07 g, 43%). MS m / z (ESI): 201.9 [M+H] + .

[0249] 1 H NMR (400MHz, CDCl3) δ8.21(d,J=8.0Hz,1H),7.73(d,J=8.0Hz,1H),3.42-3.36(m,2H),2.92-2.85(m,2H).

[0250] Preparation of Intermediate 8, 6-(Trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one

[0251] Step 1: Synthesis of ethyl 2-chloro-6-(trifluoromethyl) nicotinate

[0252] Thionyl chloride (3.62 mL, 49.9 mmol) was added dropwise to a nitrogen-protected solution of 2-chloro-6-(trifluoromethyl)nicotinic acid (7.5 g, 33.25 mmol) in ethanol (150 mL) at room temperature. The reaction mixture was then heated to 70°C and stirred for 14 hours. After completion of the reaction, the reaction mixture was concentrated to remove the ethanol, and the residue was dissolved in ethyl acetate (200 mL). The organic phase was washed with water (100 mL x 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrated product was separated by column chromatography (85% ethyl acetate-petroleum ether) to afford ethyl 2-chloro-6-(trifluoromethyl)nicotinate (7.72 g, 30.44 mmol, 92%). MS m / z (ESI): 254.0 [M+H] + .

[0253] 1 H NMR (400MHz, CDCl3) δ8.30(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),4.46(d,J=7.2Hz,2H),1.43(d,J=7.2Hz,3H).

[0254] Step 2: Synthesis of ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate

[0255] Sodium hydride (15.22 g, 380.5 mmol, 60% purity) was added portionwise to a solution of ethyl glycolate (36.7 mL, 380.5 mmol) in ethylene glycol dimethyl ether (530 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 30 minutes. Ethyl 2-chloro-6-(trifluoromethyl)nicotinate (38.6 g, 152.2 mmol) was then dissolved in ethylene glycol dimethyl ether (530 mL) and added dropwise to the reaction mixture. The mixture was allowed to react at 35°C for 2 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The organic phase was extracted, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the product was slurried with acetonitrile (300 mL) to yield ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate (29.5 g, 107.2 mmol, 70%).

[0256] 1H NMR (400MHz, DMSO-d6) δ8.24(d,J=7.6Hz,1H),7.59(d,J=7.6Hz,1H),4.17(q,J=7.2Hz,2H),1.26(t,J=7.2Hz,3H).

[0257] Step 3: Synthesis of 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one

[0258] Ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate (2.83 g, 10.28 mmol) was dissolved in a mixture of tetrahydrofuran (32.0 mL) and water (8.0 mL), and lithium hydroxide monohydrate (1.73 g, 41.1 mmol) was added. The mixture was heated to 40°C and allowed to react for 2 days. The reaction was complete. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with tetrahydrofuran. The filter cake was then dissolved in a mixture of ethyl acetate and water and acidified to a pH of 6-7 with 1 M hydrochloric acid in an ice-water bath. The layers were separated, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation to yield 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one (1.43 g, 7.04 mmol, 68%). MS m / z(ESI):204.0[M+H] + .

[0259] 1 H NMR (400MHz, CDCl3) δ8.23 (d, J = 7.6Hz, 1H), 7.52 (d, J = 7.6Hz, 1H), 4.85 (s, 2H).

[0260] Preparation of Intermediate 9, (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine

[0261] Step 1: Synthesis of (R)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-3-ol

[0262] Dissolve (R)-Me-CBS (5.94 g, 21.416 mmol) in tetrahydrofuran (1100 mL) and cool to 0°C. Add borane dimethyl sulfide complex (53.5 mL, 107.1 mmol, 2 M in THF) and stir for 1 hour. Cool the reaction system to -70°C and add 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one (14.5 g, 71.4 mmol) in tetrahydrofuran (140 mL) dropwise to the reaction system. Stir at this temperature for 1 hour, then raise the temperature to -10°C and continue stirring for 2 hours. Check the reaction is complete, quench with methanol, and stir at room temperature for 30 minutes. Add 70 mL of aqueous ammonia, stir, pour off the supernatant, and concentrate. The residue is separated by silica gel column chromatography (dichloromethane / ethyl acetate = 10 / 1) to obtain (R)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-ol (12.0 g, 58.5 mmol, 82%). MS m / z (ESI): 205.9 [M+H] + Step 2: Synthesis of (S)-3-azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine

[0263] (R)-6-(Trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-ol (12 g, 58.5 mmol) was dissolved in tetrahydrofuran (100 mL), cooled to 0°C, and diphenylphosphoryl azide (15.2 mL, 70.2 mmol) and DBU (10.5 mL, 70.2 mmol) were added. The mixture was allowed to warm to room temperature and allowed to react for 18 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was dried and concentrated, and then separated by silica gel column chromatography to obtain (S)-3-azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine (12.5 g, 54.3 mmol, 93%). MS m / z (ESI): 231.0 [M+H] + .

[0264] Step 3: Synthesis of (S)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride

[0265] (S)-3-Azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine (12.5 g, 54.3 mmol) was dissolved in tetrahydrofuran (200 mL) and water (6 mL). Triphenylphosphine (42.74 g, 162.9 mmol) was added and the reaction temperature was raised to 50°C for 18 hours. After completion of the reaction, 0.5 M hydrochloric acid was added and the mixture was extracted three times with ethyl acetate. The aqueous phase was concentrated to yield (S)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride (11.0 g, 45.7 mmol, 84%). MS m / z (ESI): 205.1 [M+H] + .

[0266] Step 4: Synthesis of (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine

[0267] Dissolve (S)-6-(Trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride (5.5 g, 22.9 mmol) in dioxane (500 mL), add 4-bromo-1-methyl-1H-pyrazole (4.23 g, 26.3 mmol), methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (5.45 g, 6.86 mmol), and sodium tert-butoxide (6.59 g, 68.58 mmol). After nitrogen purge three times, heat to 95°C and react for 2 hours. Cool to room temperature, add water, and extract with ethyl acetate. The organic phase obtained by separation was dried and concentrated, and then purified by silica gel column chromatography (PE / EA = 1 / 10) and then by C18 reverse phase column chromatography (Water (10 mM NH4HCO3)-ACN: 21%-51%) to afford (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine (2.4 g, 8.44 mmol, 37%). MS m / z (ESI): 285.1 [M+H] + .

[0268] 1H NMR (400MHz, DMSO-d6) δ7.88(d,J=7.4Hz,1H),7.41(d,J=7.4Hz,1H),7.22(d,J=1.0Hz,1H),7.02(d,J=1.0Hz,1H),5.1 9(d,J=8.9Hz,1H), 5.02(td,J=8.5,4.5Hz,1H), 4.84(dd,J=9.6,8.1Hz,1H), 4.38(dd,J=9.6,4.6Hz,1H), 3.71(s,3H).

[0269] Intermediates 10 to 19 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 9:

[0270] Preparation of Intermediate 20, (R)-N-(cyclopropylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine

[0271] Step 1: Synthesis of (R)-N-(cyclopropylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine

[0272] (R)-5-(Trifluoromethyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (200 mg, 0.84 mmol) was dissolved in a mixture of dichloromethane (3 mL) and ethanol (3 mL). Potassium acetate (82 mg, 0.84 mmol), cyclopropylcarboxaldehyde (59 mg, 0.84 mmol), acetic acid (5 mg, 0.084 mmol), and sodium triacetoxyborohydride (355 mg, 1.68 mmol) were added and stirred at room temperature overnight. The reaction solution was diluted with dichloromethane and saturated sodium bicarbonate solution, the layers were separated, and the organic phase was concentrated by rotary evaporation. The crude product was isolated by column chromatography (methanol / dichloromethane = 1 / 19) to obtain (R)-N-(cyclopropylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine (108 mg, 48%). MS m / z(ESI):256.1[M+H] + .

[0273] Intermediates 21-22 can be prepared by selecting corresponding raw materials according to the synthetic method of intermediate 20 in whole or in part:

[0274] Preparation of Intermediates 23, 24, 25, and N-(cyclopropylmethyl)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine

[0275] 2-(Trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one (1.35 g, 6.71 mmol) was dissolved in ethanol (20 mL). Cyclopropylmethylamine (1.75 mL, 20.13 mmol) and acetic acid (0.24 mL, 1.34 mmol) were added, and the mixture was stirred at 40°C overnight. The reaction solution was cooled in an ice bath, sodium borohydride (0.45 g, 13.42 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was quenched with water and extracted with ethyl acetate. The organic phase was concentrated by rotary evaporation, and the crude product was separated by column chromatography (methanol / dichloromethane = 1 / 10) to obtain (N-(cyclopropylmethyl)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (850 mg, 49%). MS m / z (ESI): 257.1 [M+H] + .

[0276] 1 H NMR (400MHz, CDCl3) δ7.79(d,J=7.8Hz,1H),7.50(d,J=7.8Hz,1H),4.35(t,J=7.0Hz,1H),3.21-3.13(m,1H),3. 04-2.95(m,1H),2.70-2.50(m,3H),1.94-1.87(m,1H),1.07-0.95(m,1H),0.55-0.47(m,2H),0.22-0.10(m,2H).

[0277] (S)-N-(Cyclopropylmethyl)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (24) (310 mg, 44%) and (R)-N-(Cyclopropylmethyl)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (25) (305 mg, 43%) were obtained by chiral preparative column separation.

[0278] Intermediates 26 to 38 can be prepared by selecting corresponding raw materials according to the synthetic methods of intermediates 23, 24, and 25 in whole or in part:

[0279] 1. Preparation of Examples

[0280] Example 1: Preparation of (S)-5-amino-N-(cyclopropylmethyl)-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)benzo[c][2,6]naphthyridine-9-carboxamide

[0281] Step 1: Synthesis of N-ethyl-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine

[0282] Dissolve 5-aminobenzo[c][2,6]naphthyridine-9-carboxylic acid (67 mg, 0.28 mmol) in N,N-dimethylacetamide (3 mL), add 2-chloro-1-methylpyridinium iodide (72 mg, 0.28 mmol) and N,N-diisopropylethylamine (121 mg, 0.94 mmol), and stir at 40°C for 1 hour. Add (S)-N-(cyclopropylmethyl)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (60 mg, 0.23 mmol) to the reaction mixture, and continue stirring at 40°C overnight. The reaction mixture was directly separated by reverse phase separation (40% acetonitrile-10 mM aqueous ammonium bicarbonate system) and lyophilized to give (S)-5-amino-N-(cyclopropylmethyl)-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)benzo[c][2,6]naphthyridine-9-carboxamide (37 mg, yield: 33%). MS m / z (ESI): 478.2 [M+H] + .

[0283] 1 H NMR(400MHz,MeOH-d4)δ10.00(s,1H),8.80(d,J=5.6Hz,1H),8.71(s,1H),8.17(d,J=5.6Hz,1H),8.09(d,J=7.9Hz,1H),7.70-7 .67(m,3H),5.63-5.56(m,1H),3.54-3.35(m,2H),2.87-2.52(m,4H),1.16-1.01(m,1H),0.55-0.45(m,2H),0.14-0.01(m,2H).

[0284] Example 2: Preparation of (S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-yl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide

[0285] Step 1: Synthesis of 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl chloride hydrochloride

[0286] 4-Amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid (100 mg, 0.38 mmol) was placed in dichloromethane (10 mL), and 1,4-dioxane hydrochloride (0.5 mL, 2.0 mmol, 4 mol / L) was added. The mixture was stirred at room temperature for half an hour, and the reaction solution was concentrated to dryness by rotary evaporation under reduced pressure. Thionyl chloride (1.0 mL, 13.79 mmol) was added to the residue, and the reaction was stirred at 70°C overnight. The reaction solution was concentrated by rotary evaporation under reduced pressure, and the residue was added to dry dichloromethane (5 mL). After rotary evaporation, 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl chloride hydrochloride (118 mg, yield: 99%) was obtained. MS m / z (ESI): 275.2 [M+H] + Step 2: Synthesis of (S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-yl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide

[0287] 4-Amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl chloride hydrochloride (119 mg, 0.38 mmol) was placed in dichloroethane (6 mL), and pyridine (0.26 mL, 3.20 mmol) and (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine (96 mg, 0.34 mmol) were added, and the reaction was stirred at 70°C for 4 hours. After the reaction, saturated sodium bicarbonate solution and dichloromethane were added, the mixture was filtered and separated, the aqueous phase was extracted with dichloromethane, the organic phase was concentrated by rotary evaporation, and the crude product was separated by silica gel column chromatography [5% methanol-dichloromethane system] to obtain (S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-yl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide (140 mg, yield: 82%). MS m / z (ESI): 527.2 [M+H] + .

[0288] 1H NMR(400MHz,MeOH-d4)δ8.26(d,J=7.1Hz,1H),8.18(s,1H),8.14(d,J=7.5Hz,1H),7.48-7.42(m,2H),7.15-7.0 5(m,2H),6.67(d,J=8.3Hz,1H),4.99(t,J=9.7Hz,1H),4.85(dd,J=10.8,3.8Hz,1H),4.41(s,3H),3.57(s,3H).

[0289] Examples 6 to 238 can be prepared by selecting corresponding raw materials according to all or part of the synthesis method of Example 1 or Example 2:

[0290] The NMR data of the compound prepared in the above example are as follows:

[0291] Biological test evaluation

[0292] 1. Human Colon Cancer HCT116 Cell Proliferation Inhibition Assay

[0293] 1. HCT 116 MTAP knockout and MTAP wild-type cells were plated in 96-well flat-bottom plates and cultured overnight in McCoy's 5A medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO2.

[0294] 2. On the second day, dissolve the compound in DMSO, dilute the compound with DMSO and culture medium in sequence and transfer to the cell plate. The final concentration of the compound is 10 μM, 4-fold dilution, 9 concentration gradients plus DMSO control.

[0295] 3. Remove cells that have not been treated with the compound and detect cell viability using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the kit instructions. Then place the cell plate on the EnVision Multilabel Reader to detect the luminescence signal.

[0296] 4. At the same time, the cell plates treated with the compounds were cultured at 37°C and 5% CO2 for 6 consecutive days.

[0297] 5. Then, use CellTiter-Glo to detect cell activity.

[0298] 6. Finally, the dose-response curve was drawn using the four-parameter dose-response curve module of GraphPad Prism v 9.2.0 software and the IC of proliferation inhibition was calculated. 50 (Unit: nM). The test results are as follows:

[0299] Table 1: Biological test results

[0300] Judging from the biological activity data of the compounds in the specific examples, the series of compounds of the present invention have a strong inhibitory effect on the proliferation of human colon cancer HCT116 MTAP knockout cells at the cellular level, and some compounds have a weaker inhibitory effect on MTAP wild-type HCT116 cells, showing high selectivity.

[0301] Pharmacokinetics in mice

[0302] 1. Research Objectives

[0303] The purpose of this study is to study the pharmacokinetic behavior of some compounds of the present invention. The administration methods are: single oral administration (PO) to ICR mice, with a dosage of 10 mg / kg.

[0304] 2. Experimental Plan

[0305] 2.1 Investigational Drugs

[0306] The compounds used in this test are from the specific examples of the present invention.

[0307] 2.2 Experimental animals

[0308] ICR mice male N=3 Original source: Shanghai Xipul-Bikai Laboratory Animal Co., Ltd.

[0309] 2.3 Drug preparation and administration

[0310] Weigh each compound and dissolve it in a solvent consisting of 20% PG, 10% Solutol HS15, and 70% pH 3 citrate buffer. Shake well and sonicate to create a colorless, clear solution. Nine mice were fasted overnight and administered orally at a dose of 10 mg / kg.

[0311] 2.4 Sample collection

[0312] 1) Approximately 90 μL of blood was collected from the submandibular vein at each time point. Anticoagulated with sodium heparin, placed on ice, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 8000 rpm, 6 minutes, 2-8 degrees Celsius).

[0313] 2) Blood samples were collected at 1, 4, and 24 hours. The samples were stored in a refrigerator at -20 degrees Celsius.

[0314] 3) To 40 μL of plasma sample, add 160 μL of ice-cold acetonitrile containing internal standard, vortex for 3 minutes, and centrifuge at 11,000 rpm for 5 minutes.

[0315] 4) Take 100 μL of the supernatant and add it to 100 μL of water. Take 5 μL and inject it into LC / MS / MS for analysis.

[0316] 3. Blood-brain barrier penetration analysis

[0317] Kp is calculated using the AUC or concentration in the brain or plasma measured by the above method. Kp refers to the relationship between drug concentrations in the brain and blood and is used to assess the drug's ability to penetrate the blood-brain barrier. Post-dose Kp is calculated using the following formula:

[0318] Kp = [AUC (brain) / AUC (plasma)], or Kp = [drug concentration (brain) / drug concentration (plasma)]

[0319] Table 2: Kp data of example compounds and comparative compounds

[0320] It can be seen from the above data that compared with the comparative compound 2, the compounds of the present invention have significantly higher Kp and have better brain barrier penetration properties than the comparative compounds in the prior art.

[0321] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N; Ring A is C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, and the C 3-10 The cycloalkyl group or the 4-10 membered heterocyclic group is further fused to C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is further fused to C 3-10 Cycloalkyl or 4-10 membered heterocyclic group; Ring B is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkyne Base, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 ; Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, Isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent; Each r is independently 0, 1, or 2; m is selected from 0, 1, 2, 3, 4, 5 or 6; and n is selected from 0, 1, 2, 3, 4 or 5.

2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring A is C 3-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 aryl or 5-8 membered heteroaryl, and the C 3-8 The cycloalkyl or 4-8 membered heterocyclic group is further fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is further fused to C 3-8 Cycloalkyl or 4-8 membered heterocyclic group; Ring B is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as defined in claim 1.

3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.

4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following structure: wherein X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N; Y1 is CR 1a or N; Y2 is CR 1b or N; Y3 is CR 1c or N; Y4 is CR 1d or N; Z is -C(R 1e R 1f )-、-C(R 1e R 1f )O-、-N(R 1g )-, -O-, or -S-; Ring B is C 4-6 Cycloalkyl, 4-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl; R 1a 、R 1b 、R 1c 、R 1d are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 , or, R 1e and R 1f Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR 10 and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ; o is 0, 1, 2, or 3; m1 is 0, 1, or 2; Among them, R9, R 10 、R 11 、R 12 、R 13 , n and r are as defined in claim 1.

5. The compound of formula (I) according to claim 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B together with its directly connected parts forms the following structure: Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 ,superior The groups are optionally further substituted independently with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; X1 is CR6 or N, each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; X2 is CR7 or N, each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as defined in claim 4.

6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following structure: Wherein, X1 is CR6 or N; X2 is CR7 or N; Y1 is CR 1a or N; Y2 is CR 1b or N; Z is -C(R 1e R 1f )-、-C(R 1e R 1f )O-、-N(R 1g )-or-O-; Ring B together with its directly connected parts forms the following structure: R 1a 、R 1b are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 alkyl Base, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, hydroxyl, C 1-4 Alkoxy and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -OR 10 and -C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R6 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ; R7 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ; R8 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 ; o is 1 or 2; m1 is 0, 1, or 2; Among them, R9, R 10 、R 11 、R 12 、R 13 , n and r are as defined in claim 1.

7. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Y1 is CH or N; Y2 is CR 1b ; R 1b Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Among them, R 10 As defined in claim 6.

8. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 1e 、R 1f are each independently selected from hydrogen, deuterium, halogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; R 1g Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, hydroxyl, methoxy and acetyl, the above groups are independently optionally further selected from one or more of the above groups are independently optionally further selected from one or more of deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Each R 1h are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Among them, R 10 As defined in claim 6.

9. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each X1 is independently CR6 or N; each X2 is independently CH; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Among them, R 10 As defined in claim 6.

10. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 substituted by aryl, 5-8 membered heteroaryl, =O, =S and -SF5; Among them, R 10 As defined in claim 6.

11. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 、-OC(O)R 11 、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Preferably, R2 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl alkyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, carboxyl, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropyloxycarbonyl, formyl, acetyl, n-propionyl, isopropionyl, formyloxy, acetoxy, n-propionyloxy, isopropionyloxy, amino, mono C 1-4 Alkylamino and di-C 1-4 The amino group is substituted by an alkylamino group.

12. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following structures: Each R 1b Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, trifluoromethoxy, difluoromethoxy, trideuteriomethoxy, dideuteriomethoxy, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, phenyl and methyl-substituted pyrazolyl.

13. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following structures: Each R 1b Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, trifluoromethoxy, difluoromethoxy, trideuteriomethoxy, dideuteriomethoxy, cyclopropyl and methyl-substituted pyrazolyl.

14. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structure: in, Selected from the following structures: Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl; Ring B and its directly connected part Selected from the following structures: Each X1 is independently CR6 or N; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy; Each R 5a Each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, the above groups are optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoro substituted by methyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5; Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5; R is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, and the above groups are independently optionally further substituted by one or more deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopentyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl. propyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, hydroxy and methoxy; provided that when R2 is selected from methyl, Not for 15. The compound of formula (I) according to claim 14, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl; R6 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy; R2 is selected from cyclopropyl-substituted methyl, cyclobutyl-substituted methyl, thiazolyl-substituted methyl, pyrimidinyl-substituted methyl, ethyl, cyclopropyl-substituted ethyl, cyclobutyl-substituted ethyl, 2,2,2-trifluoroethyl, methoxyethyl, thiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, cyclopropyl, methyl-substituted pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl.

16. The compound of formula (I) according to claim 15, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structure: in, Selected from the following structures: Each R 1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy and cyclopropyl; R6 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.

17. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structure: in, Selected from the following structures: Each R 1b each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl and methyl substituted pyrazolyl; Ring B and its directly connected part Selected from the following structures: Each X1 is independently CR6 or N; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy; Each R 5a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5; Each R 5b Each is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl and hydroxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5; Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, -SF5, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy and cyclobutyloxy, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, phenyl, =O, =S and -SF5; wherein R2 is as defined in claim 6.

18. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B and its directly connected part Selected from the following structures: Each X1 is independently CR6; each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5a are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl; Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.

19. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from substituted methyl, substituted ethyl, substituted or unsubstituted n-propyl, substituted isopropyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, The substituents of the substituted methyl, substituted ethyl, substituted n-propyl and substituted isopropyl are each independently one or more selected from fluorine, chlorine, bromine, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, -SF5, hydroxyl and methoxy, The bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl are each independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, oxetanyl, azetidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, =O, =S, -SF5, hydroxyl and methoxy.

20. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from substituted methyl, substituted ethyl, substituted or unsubstituted n-propyl, substituted isopropyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl, The substituents of the substituted methyl, substituted ethyl, substituted n-propyl and substituted isopropyl are each independently one or more selected from fluorine, chlorine, bromine, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl and methoxy, The phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl groups are each independently further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, cyclopropyl, -SF5, hydroxyl and methoxy.

21. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from trifluoromethyl, pyrazolyl-substituted methyl, imidazolyl-substituted methyl, triazolyl-substituted methyl, oxazolyl-substituted methyl, thiazolyl-substituted methyl, isothiazolyl-substituted methyl, thiadiazolyl-substituted methyl, pyrimidinyl-substituted methyl, fluoro-substituted ethyl, methoxyethyl, pyrazolyl-substituted ethyl, imidazolyl-substituted ethyl, triazolyl-substituted ethyl, oxazolyl-substituted ethyl, thiazolyl-substituted ethyl, isothiazolyl-substituted ethyl, thiadiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, pyrazolyl, methyl-substituted pyrazolyl, imidazolyl, methyl-substituted imidazolyl, triazolyl, methyl-substituted triazolyl, oxazolyl, methyl-substituted oxazolyl, thiazolyl, methyl-substituted thiazolyl, isothiazolyl, methyl-substituted isothiazolyl, thiadiazolyl, methyl-substituted thiadiazolyl, pyrimidinyl and methyl-substituted pyrimidinyl.

22. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from thiazolyl-substituted methyl, pyrimidinyl-substituted methyl, 2,2,2-trifluoroethyl, methoxyethyl, thiazolyl-substituted ethyl, pyrimidinyl-substituted ethyl, methoxy-substituted isopropyl, methyl-substituted pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl and pyrimidinyl.

23. The compound of formula (I) according to claim 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R2 is selected from the following structures:

24. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following structures: compound of formula (Vb1), compound of formula (Vb2), compound of formula (Vb3), and compound of formula (Vb4): Each R 1b each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy and cyclopropyl; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano and methyl; Each R 5b Each is independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuterium and cyclopropyl.

25. The compound of formula (I) according to any one of claims 1 to 24, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:

26. A method for preparing the compound of formula (I) according to claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, characterized in that: The steps include: wherein X is fluorine, chlorine, bromine or hydroxyl, and ring A, ring B, X1, X2, X3, R1, R2, R3, R4, R5, m and n are as described in claim 1.

27. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 25, its stereoisomers or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

28. Use of the compound of formula (I) according to any one of claims 1 to 25, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a drug for treating MATP-related cancers or tumors.

29. The use according to claim 28, characterized in that The tumor or cancer is selected from the group consisting of endometrial adenocarcinoma, granulosa-theca tumor, Sertoli cell tumor, germ cell tumor, malignant teratoma, squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma, clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, fallopian tube carcinoma, adenocarcinoma, Wilms' tumor, lymphoma, leukemia, bladder cancer, squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, prostate cancer, seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, and lipoma; Liver cancer, bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary cancer, bile duct cancer, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus, dysplastic nevus, lipoma, hemangioma, acute and chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin's lymphoma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochondroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, giant cell tumor, angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyomas, fibromas, lipomas and teratomas, branch Tracheal lung cancer, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma, gastric cancer, lymphoma, leiomyosarcoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, viper tumor, adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma, colorectal gland Carcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma, skull tumor, hemangioma, granuloma, xanthomas, osteitis deformans, meningioma, meningiosarcoma, gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor, spinal neurofibroma, meningioma, glioma, or sarcoma.

30. The use according to claim 29, characterized in that The cancer or tumor is selected from breast cancer, pancreatic cancer, skin cancer, bladder cancer, liver cancer or head and neck cancer.

31. A compound of formula (I) according to any one of claims 1 to 25, a stereoisomer thereof or a pharmaceutically acceptable salt thereof for use as a PRMT5 inhibitor.